Literature DB >> 19059257

Rare birds in North America: acute hepatitis C cohorts.

Andrea L Cox, Kimberly Page, Julie Bruneau, Naglaa H Shoukry, Georg M Lauer, Arthur Y Kim, Hugo R Rosen, Hank Radziewicz, Arash Grakoui, Daniel S Fierer, Andrea D Branch, David E Kaplan, Kyong-Mi Chang.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 19059257      PMCID： PMC4143376          DOI： 10.1053/j.gastro.2008.11.049

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  27 in total

1.  High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection.

Authors:  Alleluiah Rutebemberwa; Stuart C Ray; Jacquie Astemborski; Jordana Levine; Lin Liu; Kimberly A Dowd; Shalyn Clute; Changyu Wang; Alan Korman; Alessandro Sette; John Sidney; Drew M Pardoll; Andrea L Cox
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

2.  Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection.

Authors:  S A Villano; D Vlahov; K E Nelson; S Cohn; D L Thomas
Journal:  Hepatology       Date:  1999-03       Impact factor: 17.425

3.  Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers.

Authors:  Cheryl L Day; Nilufer P Seth; Michaela Lucas; Heiner Appel; Laurent Gauthier; Georg M Lauer; Gregory K Robbins; Zbigniew M Szczepiorkowski; Deborah R Casson; Raymond T Chung; Shannon Bell; Gillian Harcourt; Bruce D Walker; Paul Klenerman; Kai W Wucherpfennig
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

4.  Impaired hepatitis C virus (HCV)-specific effector CD8+ T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver during the chronic phase of infection.

Authors:  Henry Radziewicz; Chris C Ibegbu; Huiming Hon; Melissa K Osborn; Kamil Obideen; Mohammad Wehbi; Gordon J Freeman; Jeffrey L Lennox; Kimberly A Workowski; Holly L Hanson; Arash Grakoui
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

5.  Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells.

Authors:  Gamal Badr; Nathalie Bédard; Mohamed S Abdel-Hakeem; Lydie Trautmann; Bernard Willems; Jean-Pierre Villeneuve; Elias K Haddad; Rafick P Sékaly; Julie Bruneau; Naglaa H Shoukry
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

6.  Hepatitis C virus seroconversion among young injection drug users: relationships and risks.

Authors:  Judith A Hahn; Kimberly Page-Shafer; Paula J Lum; Philippe Bourgois; Ellen Stein; Jennifer L Evans; Michael P Busch; Leslie H Tobler; Bruce Phelps; Andrew R Moss
Journal:  J Infect Dis       Date:  2002-11-04       Impact factor: 5.226

7.  Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire.

Authors:  Matthias Wölfl; Alleluiah Rutebemberwa; Timothy Mosbruger; Qing Mao; Hong-mei Li; Dale Netski; Stuart C Ray; Drew Pardoll; John Sidney; Alessandro Sette; Todd Allen; Thomas Kuntzen; Daniel G Kavanagh; Jürgen Kuball; Philip D Greenberg; Andrea L Cox
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

8.  CD8 epitope escape and reversion in acute HCV infection.

Authors:  Joerg Timm; Georg M Lauer; Daniel G Kavanagh; Isabelle Sheridan; Arthur Y Kim; Michaela Lucas; Thillagavathie Pillay; Kei Ouchi; Laura L Reyor; Julian Schulze zur Wiesch; Rajesh T Gandhi; Raymond T Chung; Nina Bhardwaj; Paul Klenerman; Bruce D Walker; Todd M Allen
Journal:  J Exp Med       Date:  2004-12-20       Impact factor: 14.307

9.  Immune evasion versus recovery after acute hepatitis C virus infection from a shared source.

Authors:  Ian Tester; Susan Smyk-Pearson; Ping Wang; Anne Wertheimer; Ermei Yao; David M Lewinsohn; John E Tavis; Hugo R Rosen
Journal:  J Exp Med       Date:  2005-06-06       Impact factor: 14.307

10.  Analysis of successful immune responses in persons infected with hepatitis C virus.

Authors:  F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307
View more
  34 in total

1.  Will there be a vaccine to protect against the hepatitis C virus?

Authors:  Benoît Callendret; Christopher M Walker
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

2.  Computational reconstruction of Bole1a, a representative synthetic hepatitis C virus subtype 1a genome.

Authors:  Supriya Munshaw; Justin R Bailey; Lin Liu; William O Osburn; Kelly P Burke; Andrea L Cox; Stuart C Ray
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

3.  Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men.

Authors:  Daniel S Fierer; Douglas T Dieterich; Michael P Mullen; Andrea D Branch; Alison J Uriel; Damaris C Carriero; Wouter O van Seggelen; Rosanne M Hijdra; David G Cassagnol
Journal:  Clin Infect Dis       Date:  2013-12-13       Impact factor: 9.079

4.  Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses.

Authors:  Sandy Pelletier; Christian Drouin; Nathalie Bédard; Salim I Khakoo; Julie Bruneau; Naglaa H Shoukry
Journal:  J Hepatol       Date:  2010-07-17       Impact factor: 25.083

Review 5.  Will there be a vaccine to prevent HCV infection?

Authors:  Jonathan R Honegger; Yan Zhou; Christopher M Walker
Journal:  Semin Liver Dis       Date:  2014-04-29       Impact factor: 6.115

6.  Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil.

Authors:  Alexander M Strasak; Arthur Y Kim; Georg M Lauer; Paulo S de Sousa; Cleber F Ginuino; Carlos A Fernandes; Carlos E Velloso; Adilson J de Almeida; Jaqueline M de Oliveira; Clara F Yoshida; Julian Schulze zur Wiesch; Gláucia Paranhos-Baccalá; Stefan Lang; Larry J Brant; Hanno Ulmer; Susanne Strohmaier; Lalit Kaltenbach; Elisabeth Lampe; Lia L Lewis-Ximenez
Journal:  BMC Infect Dis       Date:  2011-01-12       Impact factor: 3.090

7.  Underascertainment of acute hepatitis C virus infections in the U.S. surveillance system: a case series and chart review.

Authors:  Shauna Onofrey; Jasneet Aneja; Gillian A Haney; Ellen H Nagami; Alfred DeMaria; Georg M Lauer; Kelsey Hills-Evans; Kerri Barton; Stephanie Kulaga; Melinda J Bowen; Noelle Cocoros; Barbara H McGovern; Daniel R Church; Arthur Y Kim
Journal:  Ann Intern Med       Date:  2015-08-18       Impact factor: 25.391

8.  Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection.

Authors:  Kimberly Page; William Osburn; Jennifer Evans; Judith A Hahn; Paula Lum; Alice Asher; Eric Delwart; Leslie Tobler; Andrea L Cox; Michael P Busch
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

9.  Cell-mediated immune responses directed against hepatitis C virus (HCV) alternate reading frame protein (ARFP) are undetectable during acute infection.

Authors:  Christian Drouin; Stéphanie Lamarche; Julie Bruneau; Hugo Soudeyns; Naglaa H Shoukry
Journal:  J Clin Virol       Date:  2009-12-01       Impact factor: 3.168

10.  Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study.

Authors:  Jason Grebely; Meghan D Morris; Thomas M Rice; Julie Bruneau; Andrea L Cox; Arthur Y Kim; Barbara H McGovern; Naglaa H Shoukry; Georg Lauer; Lisa Maher; Andrew R Lloyd; Margaret Hellard; Maria Prins; Gregory J Dore; Kimberly Page
Journal:  Int J Epidemiol       Date:  2012-11-30       Impact factor: 7.196
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.